Movatterモバイル変換


[0]ホーム

URL:


SG11201909046XA - PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY - Google Patents

PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY

Info

Publication number
SG11201909046XA
SG11201909046XASG11201909046XASG11201909046XASG 11201909046X ASG11201909046X ASG 11201909046XASG 11201909046X ASG11201909046X ASG 11201909046XASG 11201909046X ASG11201909046X ASG 11201909046XA
Authority
SG
Singapore
Prior art keywords
international
subject
treatment
april
progressive supranuclear
Prior art date
Application number
Inventor
Barbara Finck
David E Weinstein
Sarita K Jain
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences IncfiledCriticalCoherus Biosciences Inc
Publication of SG11201909046XApublicationCriticalpatent/SG11201909046XA/en

Links

Classifications

Landscapes

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT omit VIII °nolo III OH mom!! 0l Elio oimIE (10) International Publication Number WO 2018/187350 Al (51) International Patent Classification: A61K 31/47 (2006.01) A61P 25/28 (2006.01) (21) International Application Number: PCT/US2018/025923 (22) International Filing Date: 03 April 2018 (03.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/480,838 03 April 2017 (03.04.2017) US 62/651,653 02 April 2018 (02.04.2018) US (71) Applicant: COHERUS BIOSCIENCES INC. [US/US]; 333 Twin Dolphin Drive, Suite 600, Redwood City, Cali- fornia 94065 (US). (72) Inventors: FINCK, Barbara; 3858 Jackson Street, San Francisco, California 94118 (US). WEINSTEIN, David E.; 39 Round Hill Road, Dobbs Ferry, New York 10522 (US). JAIN, Smith. K.; 1267 Lakeside Dr. #1084, Sunny- vale, California 94085 (US). (74) Agent: DORIGO, Andrea et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) = (54) Title: PPARy AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY (I) (57) : Methods of treatment of progressive supranuclear palsy or its symptoms, with PPARy agonists, and in particular, the compound of formula (I) known as INT 131: Formula (I). Also provided are methods of treating a subject that include selecting a subject having an elevated level of neurofilament light chain protein in a sample obtained from the subject, as compared to a reference level of neurofilament light chain protein, and administering a pharmaceutical composition including a therapeutically effective amount of a compound of formula (I) to the selected subject. O N cc 00 O O
SG11201909046X2017-04-032018-04-03PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSYSG11201909046XA (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US201762480838P2017-04-032017-04-03
US201862651653P2018-04-022018-04-02
PCT/US2018/025923WO2018187350A1 (en)2017-04-032018-04-03PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY

Publications (1)

Publication NumberPublication Date
SG11201909046XAtrue SG11201909046XA (en)2019-10-30

Family

ID=62028150

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG11201909046XSG11201909046XA (en)2017-04-032018-04-03PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY

Country Status (12)

CountryLink
US (1)US11253508B2 (en)
EP (1)EP3606527A1 (en)
JP (1)JP2020515639A (en)
KR (1)KR20200036808A (en)
CN (1)CN110996951A (en)
AU (1)AU2018249822A1 (en)
BR (1)BR112019020485A2 (en)
CA (1)CA3058806A1 (en)
IL (1)IL269705A (en)
MX (1)MX2019011867A (en)
SG (1)SG11201909046XA (en)
WO (1)WO2018187350A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20100222489A1 (en)2009-02-272010-09-02Jiang Dayue DCopolymer composition, membrane article, and methods thereof
EP3267994A4 (en)2015-03-092018-10-31Intekrin Therapeutics, Inc.Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
MX2019011867A (en)2017-04-032020-01-09Coherus Biosciences IncPparî³ agonist for treatment of progressive supranuclear palsy.
EA201992364A1 (en)*2018-04-022020-03-23Кохерус Байосайенсис Инк. PPARγ AGONIST FOR TREATMENT OF PROGRESSING NUCLEAR PARALYSIS

Family Cites Families (399)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DE296075C (en)
US4166452A (en)1976-05-031979-09-04Generales Constantine D J JrApparatus for testing human responses to stimuli
US4256108A (en)1977-04-071981-03-17Alza CorporationMicroporous-semipermeable laminated osmotic system
US4265874A (en)1980-04-251981-05-05Alza CorporationMethod of delivering drug with aid of effervescent activity generated in environment of use
JPS61100519A (en)1984-10-231986-05-19Shin Etsu Chem Co Ltd Pharmaceutical hard capsule
US5618920A (en)1985-11-011997-04-08Xoma CorporationModular assembly of antibody genes, antibodies prepared thereby and use
DE69124371T2 (en)1990-04-141997-06-12New England Medical Center Inc TYPE IV DIPEPTIDYL AMINOPEPTIDASE INHIBITORS
US5462928A (en)1990-04-141995-10-31New England Medical Center Hospitals, Inc.Inhibitors of dipeptidyl-aminopeptidase type IV
US6407213B1 (en)1991-06-142002-06-18Genentech, Inc.Method for making humanized antibodies
US6825169B1 (en)1991-10-222004-11-30Trustees Of Tufts CollegeInhibitors of dipeptidyl-aminopeptidase type IV
DE69233671T2 (en)1991-10-222007-10-18New England Medical Center Hospitals, Inc., Boston Inhibitors of dipeptidyl aminopeptidase type IV
MX9206628A (en)1991-11-221993-05-01Boehringer Ingelheim Pharma PROLINABORONATE ESTER AND METHOD FOR ITS PREPARATION.
US5431917A (en)1992-10-081995-07-11Japan Elanco Company, Ltd.Hard capsule for pharmaceutical drugs and method for producing the same
US5424286A (en)1993-05-241995-06-13Eng; JohnExendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
IL111785A0 (en)1993-12-031995-01-24Ferring BvDp-iv inhibitors and pharmaceutical compositions containing them
US5543396A (en)1994-04-281996-08-06Georgia Tech Research Corp.Proline phosphonate derivatives
US20020006899A1 (en)1998-10-062002-01-17Pospisilik Andrew J.Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
DE19616486C5 (en)1996-04-252016-06-30Royalty Pharma Collection Trust Method for lowering the blood glucose level in mammals
AU4721897A (en)1996-10-251998-05-22Tanabe Seiyaku Co., Ltd.Tetrahydroisoquinoline derivatives
US6011155A (en)1996-11-072000-01-04Novartis AgN-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en)1996-11-072002-07-01Novartis AgN-substituted 2-cyanopyrrolidnes
US5736151A (en)1996-12-091998-04-07Pharmacia & Upjohn CompanyAntibiotic oil suspensions
AU739020B2 (en)1997-01-072001-10-04Amylin Pharmaceuticals, Inc.Use of exendins and agonists thereof for the reduction of food intake
ES2236634T3 (en)1997-04-072005-07-16Genentech, Inc. ANTI-VEGF ANTIBODIES.
US6100234A (en)1997-05-072000-08-08Tufts UniversityTreatment of HIV
US6040145A (en)1997-05-072000-03-21Tufts UniversityPotentiation of the immune response
BR9813233A (en)1997-09-292000-08-22Point Therapeutics Inc Stimulation of hematopoietic cells in vitro
WO1999025719A1 (en)1997-11-181999-05-27Zaidan Hojin Biseibutsu Kagaku Kenkyu KaiNovel physiologically active substance sulphostin, process for producing the same, and use thereof
CA2318731C (en)1998-01-292012-05-29Tularik Inc.Ppar-gamma modulators
US6583157B2 (en)1998-01-292003-06-24Tularik Inc.Quinolinyl and benzothiazolyl modulators
EP2583675A1 (en)1998-02-022013-04-24Trustees Of Tufts CollegeUse of dipeptidylpeptidase inhibitors to regulate glucose metabolism
US20020061839A1 (en)1998-03-092002-05-23Scharpe Simon LodewijkSerine peptidase modulators
US6300314B1 (en)1998-05-042001-10-09Point Therapeutics, Inc.Hematopoietic stimulation
DE19823831A1 (en)1998-05-281999-12-02Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
EP1084129B1 (en)1998-06-052003-01-22Point Therapeutics, Inc.Cyclic boroproline compounds
DE19828114A1 (en)1998-06-242000-01-27Probiodrug Ges Fuer Arzneim Produgs of unstable inhibitors of dipeptidyl peptidase IV
DE19828113A1 (en)1998-06-242000-01-05Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
DE19834591A1 (en)1998-07-312000-02-03Probiodrug Ges Fuer ArzneimUse of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia
CA2339537A1 (en)1998-08-212000-03-02Barbara WallnerRegulation of substrate activity
US6242422B1 (en)1998-10-222001-06-05Idun Pharmacueticals, Inc.(Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
JP3449253B2 (en)1998-10-292003-09-22シオノギクオリカプス株式会社 Manufacturing method of hard capsule
CN100334109C (en)1998-12-072007-08-29研究及应用科学协会股份有限公司 Glucagon-like peptide-1 analogs
KR20010093813A (en)1998-12-092001-10-29와이즈먼 앤드루Molecular scaffolds acting as templates comprising carbamate linkages
CO5150173A1 (en)1998-12-102002-04-29Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
JP2000191616A (en)1998-12-242000-07-11Senju Pharmaceut Co LtdNew peptidylaldehyde derivative and medicine containing the same
BRPI0007820B8 (en)1999-01-142021-05-25Amylin Pharmaceuticals Llc exendin agonist pharmaceutical formulations and their uses
JP3018186B1 (en)1999-03-092000-03-13大阪大学長 Anti-inflammatory, monocytic cell growth inhibitor
GB9906714D0 (en)1999-03-231999-05-19Ferring BvCompositions for improving fertility
GB9906715D0 (en)1999-03-231999-05-19Ferring BvCompositions for promoting growth
US20050272652A1 (en)1999-03-292005-12-08Gault Victor APeptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
JP3716901B2 (en)1999-04-142005-11-16シオノギクオリカプス株式会社 Cellulose ether film
JP4121215B2 (en)1999-05-172008-07-23財団法人微生物化学研究会 Sulfostin analog, and method for producing sulfostine and its analog
AU781897B2 (en)1999-05-252005-06-23Point Therapeutics, Inc.Anti-tumor comprising boroproline compounds
US6172081B1 (en)1999-06-242001-01-09Novartis AgTetrahydroisoquinoline 3-carboxamide derivatives
US6107317A (en)1999-06-242000-08-22Novartis AgN-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6110949A (en)1999-06-242000-08-29Novartis AgN-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
IL147308A0 (en)1999-06-302002-08-14Tularik IncCompounds for the modulation of pparγ activity and pharmaceutical compositions containing the same
US7041691B1 (en)1999-06-302006-05-09Amgen Inc.Compounds for the modulation of PPARγ activity
US6617340B1 (en)1999-07-292003-09-09Novartis AgN-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
DE19940130A1 (en)1999-08-242001-03-01Probiodrug Ges Fuer Arzneim New effectors of Dipeptidyl Peptidase IV for topical use
PH12000002657B1 (en)1999-10-122006-02-21Bristol Myers Squibb CoC-aryl glucoside SGLT2 inhibitors
US6515117B2 (en)1999-10-122003-02-04Bristol-Myers Squibb CompanyC-aryl glucoside SGLT2 inhibitors and method
JP2003535034A (en)1999-11-122003-11-25ギルフォード ファーマシューティカルズ インコーポレイテッド Dipeptidyl peptidase IV inhibitors and methods for producing and using dipeptidyl peptidase IV inhibitors
US20040152745A1 (en)1999-11-122004-08-05Guilford Pharmaceuticals, Inc.Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
GB9928330D0 (en)1999-11-302000-01-26Ferring BvNovel antidiabetic agents
US6380398B2 (en)2000-01-042002-04-30Novo Nordisk A/STherapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
PT1248604E (en)2000-01-212007-01-31Novartis AgCombinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
JP2003520849A (en)2000-01-242003-07-08ノボ ノルディスク アクティーゼルスカブ N-substituted 2-cyanopyrroles and -pyrrolines which are inhibitors of the enzyme DPP-IV
US6395767B2 (en)2000-03-102002-05-28Bristol-Myers Squibb CompanyCyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6608038B2 (en)2000-03-152003-08-19Novartis AgMethods and compositions for treatment of diabetes and related conditions via gene therapy
CN101690815A (en)2000-03-312010-04-07普罗西迪恩有限公司Novel use of dipeptidyl peptidase-iv inhibitor
GB0010188D0 (en)2000-04-262000-06-14Ferring BvInhibitors of dipeptidyl peptidase IV
GB0010183D0 (en)2000-04-262000-06-14Ferring BvInhibitors of dipeptidyl peptidase IV
AU2001252612A1 (en)2000-04-282001-11-12Sankyo Company, LimitedPpargamma modulators
AU6118001A (en)2000-05-032001-11-12Tularik IncCombination therapeutic compositions and methods of use
US6432969B1 (en)2000-06-132002-08-13Novartis AgN-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW583185B (en)2000-06-132004-04-11Novartis AgN-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
US7078397B2 (en)2000-06-192006-07-18Smithkline Beecham CorporationCombinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB0014969D0 (en)2000-06-192000-08-09Smithkline Beecham PlcNovel method of treatment
US20030171399A1 (en)2000-06-282003-09-11Tularik Inc.Quinolinyl and benzothiazolyl modulators
HK1052351B (en)2000-06-282006-11-03Japan Tobacco Inc.Benzothiazolyl ppar-gamma modulators
WO2002002560A2 (en)2000-07-042002-01-10Novo Nordisk A/SPurine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
PT1308439E (en)2000-08-102008-12-12Mitsubishi Tanabe Pharma CorpProline derivatives and use thereof as drugs
JP4329291B2 (en)2000-10-062009-09-09田辺三菱製薬株式会社 Nitrogen-containing five-membered ring compounds
JP2004035574A (en)2000-10-062004-02-05Tanabe Seiyaku Co Ltd Aliphatic nitrogen-containing five-membered ring compound
JP4329290B2 (en)2000-10-062009-09-09田辺三菱製薬株式会社 Aliphatic nitrogen-containing five-membered ring compounds
DK1323710T3 (en)2000-10-062008-12-01Mitsubishi Tanabe Pharma Corp Nitrogen-containing five-membered ring compounds
AUPR107800A0 (en)2000-10-272000-11-23University Of Sydney, ThePeptide and nucleic acid molecule ii
TWI243162B (en)2000-11-102005-11-11Taisho Pharmaceutical Co LtdCyanopyrrolidine derivatives
JPWO2002051836A1 (en)2000-12-272004-04-22協和醗酵工業株式会社 Dipeptidyl peptidase-IV inhibitor
ATE534433T1 (en)2001-01-022011-12-15Imtm Gmbh COMBINED USE OF ENZYMIN HIBITORS FOR THE THERAPY AND PREVENTION OF ALLERGIC REACTIONS OF TYPE I ACCORDING TO GELL AND COOMBS AND FOR THE THERAPY AND PREVENTION OF DERMATOLOGICAL DISEASES WITH FOLLICULAR AND EPIDERMAL HYPERKERATOSIS AND INCREASE KERATINOCYTE PROLIFERATION
DE10100053A1 (en)2001-01-022002-08-22Keyneurotek Ag I G Use of enzyme inhibitors of dipeptidyl peptidase IV and aminopeptidase N and pharmaceutical preparations therefrom for the prevention and / or therapy of ischemia-related acute and chronic neurodegenerative processes and diseases
EP1352655A4 (en)2001-01-162006-11-02Nippon Kayaku Kk REMEDIES FOR THE TREATMENT OF BONE MARROW REMOVAL AND INFECTIOUS DISEASES AND AGENTS FOR INCREASING LEUKOCYTIC CONCENTRATION OF BLOOD
PL364221A1 (en)2001-02-022004-12-13Takeda Chemical Industries, Ltd.Fused heterocyclic compounds
JP4213390B2 (en)2001-02-022009-01-21武田薬品工業株式会社 Fused heterocyclic compounds
RS55023B1 (en)2001-02-242016-11-30Boehringer Ingelheim PharmaXantine derivatives, production and use thereof as a medicament
JP2002265439A (en)2001-03-082002-09-18Mitsubishi Pharma Corp Cyanopyrrolidine derivatives and their pharmaceutical uses
DE60226723D1 (en)2001-03-272008-07-03Merck & Co Inc DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
FR2822826B1 (en)2001-03-282003-05-09Servier Lab NOVEL ALPHA-AMINO ACID SULPHONYL DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US6890905B2 (en)2001-04-022005-05-10Prosidion LimitedMethods for improving islet signaling in diabetes mellitus and for its prevention
GB0109146D0 (en)2001-04-112001-05-30Ferring BvTreatment of type 2 diabetes
US6573287B2 (en)2001-04-122003-06-03Bristo-Myers Squibb Company2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
FR2824825B1 (en)2001-05-152005-05-06Servier Lab NOVEL ALPHA-AMINOACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US20030060494A1 (en)2001-05-182003-03-27Nobuyuki YasudaPharmaceutical use of N-carbamoylazole derivatives
WO2003000180A2 (en)2001-06-202003-01-03Merck & Co., Inc.Dipeptidyl peptidase inhibitors for the treatment of diabetes
ATE318139T1 (en)2001-06-202006-03-15Merck & Co Inc DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES
GB0115517D0 (en)2001-06-252001-08-15Ferring BvNovel antidiabetic agents
DE10154689A1 (en)2001-11-092003-05-22Probiodrug Ag Substituted amino ketone compounds
RU2299066C2 (en)2001-06-272007-05-20Пробиодруг АгNovel inhibitors of dipeptidyl peptidase iv and their using as anticancer agents
US20030130199A1 (en)2001-06-272003-07-10Von Hoersten StephanDipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
ATE380175T1 (en)2001-06-272007-12-15Smithkline Beecham Corp PYRROLIDINE AS DIPEPTIDYL PEPTIDASE INHIBITORS
ATE370943T1 (en)2001-06-272007-09-15Smithkline Beecham Corp FLUOROPYRROLIDINE AS DIPEPTIDYL-PEPTIDASE INHIBITORS
JP2004521149A (en)2001-06-272004-07-15プロバイオドラッグ アーゲー Novel dipeptidyl peptidase IV inhibitors and their use as anticancer agents
US7368421B2 (en)2001-06-272008-05-06Probiodrug AgUse of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
WO2003002531A2 (en)2001-06-272003-01-09Smithkline Beecham CorporationFluoropyrrolidines as dipeptidyl peptidase inhibitors
US6869947B2 (en)2001-07-032005-03-22Novo Nordisk A/SHeterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1404675B1 (en)2001-07-032008-03-12Novo Nordisk A/SDpp-iv-inhibiting purine derivatives for the treatment of diabetes
UA74912C2 (en)2001-07-062006-02-15Merck & Co IncBeta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
SG143981A1 (en)2001-08-312008-07-29Semiconductor Energy LabLaser irradiation method, laser irradiation apparatus, and method of manufacturing a semiconductor device
US6844316B2 (en)2001-09-062005-01-18Probiodrug AgInhibitors of dipeptidyl peptidase I
DE10143840A1 (en)2001-09-062003-03-27Probiodrug AgNew acylated hydroxamates useful for the treatment of e.g. wound healing
JPWO2003024942A1 (en)2001-09-142004-12-24三菱ウェルファーマ株式会社 Thiazolidine derivatives and their pharmaceutical uses
EP1463727A2 (en)2001-09-192004-10-06Novo Nordisk A/SHeterocyclic compounds that are inhibitors of the enzyme dpp-iv
GB0125445D0 (en)2001-10-232001-12-12Ferring BvProtease Inhibitors
GB0125446D0 (en)2001-10-232001-12-12Ferring BvNovel anti-diabetic agents
US6861440B2 (en)2001-10-262005-03-01Hoffmann-La Roche Inc.DPP IV inhibitors
BR0213958A (en)2001-10-312004-09-08Novartis Ag Methods for treating diabetes and related conditions based on tcf1 gene polymorphisms
US20030125304A1 (en)2001-11-092003-07-03Hans-Ulrich DemuthSubstituted amino ketone compounds
US7236683B2 (en)2001-11-152007-06-26Macrovision CorporationMethod and apparatus for providing or enhancing copy protection by adding selected negative-going and positive-going pulses in a video signal HBI
WO2003045228A2 (en)2001-11-262003-06-05Trustees Of Tufts CollegeMethods for treating autoimmune disorders, and reagents related thereto
EP2316470A3 (en)2001-11-262011-08-24Trustees Of Tufts CollegePeptidomimetic inhibitors of post-proline cleaving enzymes
AU2002360732A1 (en)2001-12-262003-07-24Guilford PharmaceuticalsChange inhibitors of dipeptidyl peptidase iv
US6727261B2 (en)2001-12-272004-04-27Hoffman-La Roche Inc.Pyrido[2,1-A]Isoquinoline derivatives
US6725848B2 (en)2002-01-182004-04-27Detroit Diesel CorporationMethod of controlling exhaust gas recirculation system based upon humidity
US20030232788A1 (en)2002-02-082003-12-18Idun Pharmaceuticals, Inc.(Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases
KR100618752B1 (en)2002-02-132006-08-31에프. 호프만-라 로슈 아게 Novel pyridine- and quinoline-derivatives
JP4359146B2 (en)2002-02-132009-11-04エフ.ホフマン−ラ ロシュ アーゲー Novel pyridine- and pyrimidine-derivatives
US6906074B2 (en)2002-02-222005-06-14Nippon Zoki Pharmaceutical Co., Ltd.2-phenylpiperazine derivatives
US7074798B2 (en)2002-02-252006-07-11Eisai Co., LtdXanthine derivative and DPPIV inhibitor
JP2004043429A (en)2002-02-252004-02-12Eisai Co LtdNew xanthine derivative and dppiv inhibitor
DK1480961T3 (en)2002-02-282007-05-07Prosidion Ltd Glutaminyl-based DPIV inhibitors
HUP0200849A2 (en)2002-03-062004-08-30Sanofi-SynthelaboN-aminoacetyl-pyrrolidine-2-carbonitrile derivatives, pharmaceutical compositions containing them and process for producing them
WO2003080633A1 (en)2002-03-252003-10-02Nippon Kayaku Kabushiki KaishaNovel $g(a)-amino-n-(diaminophosphinyl)lactam derivative
ATE373660T1 (en)2002-03-252007-10-15Merck & Co Inc HETEROCYCLIC BETA-AMINO COMPOUNDS AS INHIBITORS OF DIPEPTIDYLPEPTIDASE FOR TREATMENT OR PREVENTION OF DIABETES
JP4329382B2 (en)2002-04-042009-09-09田辺三菱製薬株式会社 Pharmaceutical composition
JP4329381B2 (en)2002-04-042009-09-09田辺三菱製薬株式会社 Pharmaceutical composition
CA2481995A1 (en)2002-04-082003-10-16Torrent Pharmaceuticals Ltd.Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
US20040106802A1 (en)2002-04-082004-06-03Torrent Pharmaceuticals Ltd.Novel compounds and therapeutic uses thereof
JP2003300977A (en)2002-04-102003-10-21Sumitomo Pharmaceut Co Ltd Xanthine derivative
JP2004026820A (en)2002-05-092004-01-29Taisho Pharmaceut Co Ltd Dipeptidyl peptidase IV inhibitor
JPWO2003095425A1 (en)2002-05-092005-09-15大正製薬株式会社 Cyanopyrrolidine derivatives
JP2003327532A (en)2002-05-102003-11-19Takeda Chem Ind LtdPeptidase inhibitor
GB0212412D0 (en)2002-05-292002-07-10Novartis AgCombination of organic compounds
WO2003101448A1 (en)2002-06-032003-12-11Novartis AgThe use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
WO2003101449A2 (en)2002-06-042003-12-11Pfizer Products Inc.Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
US6710040B1 (en)2002-06-042004-03-23Pfizer Inc.Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
WO2003101958A2 (en)2002-06-042003-12-11Pfizer Products Inc.Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors
RU2297418C9 (en)2002-06-062009-01-27Эйсай Ко., Лтд.Novel condensed derivatives of imidazole, inhibitors of dipeptidyl peptidase iv, pharmaceutical composition, method of treatment and using based on thereof
HUP0202001A2 (en)2002-06-142005-08-29Sanofi-AventisAzabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity
JP2004026678A (en)2002-06-242004-01-29Microbial Chem Res Found Type 2 diabetes treatment
CA2491466A1 (en)2002-07-092004-01-15Sharlene AdamsMethods and compositions relating to isoleucine boroproline compounds
AU2003248259A1 (en)2002-07-102004-02-02Yamanouchi Pharmaceutical Co., Ltd.Novel azetidine derivative or salt thereof
JP4530852B2 (en)2002-07-152010-08-25メルク・シャープ・エンド・ドーム・コーポレイション Piperidinopyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
TW200401635A (en)2002-07-232004-02-01Yamanouchi Pharma Co Ltd2-Cyano-4-fluoropyrrolidine derivative or salt thereof
AU2003253369A1 (en)2002-07-292004-02-16Tanabe Seiyaku Co., Ltd.Three-dimensional structure of dipeptidyl peptidase iv
TW200404060A (en)2002-08-082004-03-16Takeda Chemical Industries LtdFused heterocyclic compounds
JP4542757B2 (en)2002-08-082010-09-15武田薬品工業株式会社 Fused heterocyclic compounds
US7407955B2 (en)2002-08-212008-08-05Boehringer Ingelheim Pharma Gmbh & Co., Kg8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10238243A1 (en)2002-08-212004-03-04Boehringer Ingelheim Pharma Gmbh & Co. KgNew 8-(3-amino-piperidin-1-yl)-xanthine derivatives are dipeptidylpeptidase-IV inhibitors useful for, e.g. treating diabetes mellitus, arthritis or obesity
BRPI0313648B8 (en)2002-08-212021-05-25Boehringer Ingelheim Pharma 8-[3-amino-piperidin-1-yl]-xanthines, their physiologically compatible salts, their uses and their preparation processes, as well as medicines containing them and their preparation processes
DE10238477A1 (en)2002-08-222004-03-04Boehringer Ingelheim Pharma Gmbh & Co. Kg New purine derivatives, their production and their use as medicines
DE10238470A1 (en)2002-08-222004-03-04Boehringer Ingelheim Pharma Gmbh & Co. Kg New xanthine derivatives, their production and their use as medicines
WO2004019352A1 (en)2002-08-262004-03-04Matsushita Electric Industrial Co., Ltd.Multi-phase-use magnetic element and production method therefor
BR0313831A (en)2002-08-292005-07-05Taisho Pharmaceutical Co Ltd Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives
US8895541B2 (en)2002-09-042014-11-25James A. CarnazzaMethods for inhibiting the development of huntington's disease
AU2003262059A1 (en)2002-09-112004-04-30Takeda Pharmaceutical Company LimitedSustained release preparation
US20040121964A1 (en)2002-09-192004-06-24Madar David J.Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7238724B2 (en)2002-09-192007-07-03Abbott LaboratoriesPharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7262207B2 (en)2002-09-192007-08-28Abbott LaboratoriesPharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
JP4491346B2 (en)2002-10-072010-06-30メルク・シャープ・エンド・ドーム・コーポレイション Anti-diabetic beta-amino heterocyclic dipeptidyl peptidase inhibitor
AU2003269850A1 (en)2002-10-082004-05-04Novo Nordisk A/SHemisuccinate salts of heterocyclic dpp-iv inhibitors
WO2004037169A2 (en)2002-10-182004-05-06Merck & Co., Inc.Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
ES2344057T3 (en)2002-10-232010-08-17Bristol-Myers Squibb Company INHIBITORS OF DIPEPTIDIL PEPTIDASA IV BASED ON GLICINE NITRILS.
WO2004041795A1 (en)2002-10-302004-05-21Guilford Pharmaceuticals Inc.Novel inhibitors of dipeptidyl peptidase iv
AU2003280680A1 (en)2002-11-012004-06-18Sumitomo Pharmaceuticals Co., Ltd.Xanthine compound
BR0315796A (en)2002-11-072005-09-13Merck & Co Inc Compound, Pharmaceutical Composition, and, Methods for Treating Diabetes, Treating Hyperglycemia, and Treating Obesity in a Mammal
US7482337B2 (en)2002-11-082009-01-27Boehringer Ingelheim Pharma Gmbh & Co. KgXanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10251927A1 (en)2002-11-082004-05-19Boehringer Ingelheim Pharma Gmbh & Co. KgNew 1,7,8-trisubstituted xanthine derivatives, are dipeptidylpeptidase-IV inhibitors useful e.g. for treating diabetes mellitus type I or II, arthritis or obesity
MXPA05005260A (en)2002-11-182005-07-25Pfizer Prod IncDipeptidyl peptidase iv inhibiting fluorinated cyclic amides.
DE10254304A1 (en)2002-11-212004-06-03Boehringer Ingelheim Pharma Gmbh & Co. Kg New xanthine derivatives, their production and their use as medicines
DE10256264A1 (en)2002-12-032004-06-24Boehringer Ingelheim Pharma Gmbh & Co. KgNew trisubstituted dihydro-imidazo-pyridazinone or imidazo-pyridinone derivatives, useful as dipeptidylpeptidase-IV inhibitors for e.g. treating diabetes mellitus type I or II, arthritis or obesity
US7109192B2 (en)2002-12-032006-09-19Boehringer Ingelheim Pharma Gmbh & Co KgSubstituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
UY28103A1 (en)2002-12-032004-06-30Boehringer Ingelheim Pharma NEW IMIDAZO-PIRIDINONAS REPLACED, ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS
EP1578414A4 (en)2002-12-042007-10-24Merck & Co IncPhenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7420079B2 (en)2002-12-092008-09-02Bristol-Myers Squibb CompanyMethods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
CA2505771A1 (en)2002-12-102004-06-24Novartis AgCombination of an dpp-iv inhibitor and a ppar-alpha compound
EP1583534A4 (en)2002-12-202007-08-29Merck & Co Inc3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2512546A1 (en)2003-01-172004-08-05Merck & Co., Inc.3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2004244412A (en)2003-01-202004-09-02Kotobuki Seiyaku Kk2-cyanopyrrolidine derivative having substituent at 4-position, method for producing the same, and medicament containing the same
JP4345313B2 (en)2003-01-242009-10-14株式会社日立製作所 Operation management method of storage system based on policy
KR100998796B1 (en)2003-01-312010-12-06가부시키가이샤산와카가쿠켄큐쇼 Compounds That Inhibit Dipeptidyl Peptidase IV
EP1592689A4 (en)2003-01-312008-12-24Merck & Co Inc3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004071454A2 (en)2003-02-132004-08-26Guilford Pharmaceuticals Inc.Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv
WO2004076433A1 (en)2003-02-282004-09-10AicDipeptidyl peptidase inhibitors
WO2004076434A1 (en)2003-02-282004-09-10AicDipeptidyl peptidase inhibitors
AR043515A1 (en)2003-03-192005-08-03Merck & Co Inc PROCEDURE TO PREPARE CHIRAL DERIVATIVES BETA AMINO ACIDS BY ASYMMETRIC HYDROGENATION
WO2004085661A2 (en)2003-03-242004-10-07Merck & Co., IncProcess to chiral beta-amino acid derivatives
KR20050122220A (en)2003-03-252005-12-28다케다 샌디에고, 인코포레이티드Dipeptidyl peptidase inhibitors
WO2004087650A2 (en)2003-03-272004-10-14Merck & Co. Inc.Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
WO2004092128A1 (en)2003-04-102004-10-28Smithkline Beecham CorporationAnhydrous crystalline forms of (2s, 4s)-1-{(2r)-2-amino-3-‘4-methoxybenzyl)sulfonyl!-3-methylbutanoyl}-4-fluoropyrrolindine-2-carbonitrile
JPWO2004096806A1 (en)2003-04-302006-07-13大日本住友製薬株式会社 Condensed imidazole derivatives
WO2004099134A2 (en)2003-05-052004-11-18Prosidion Ltd.Glutaminyl based dp iv-inhibitors
US20040224995A1 (en)2003-05-092004-11-11University Of North Texas Health Science Center At Fort WorthNeuroprotective effects of PPARy agonists against cellular oxidative insults
CN1787823A (en)2003-05-142006-06-14麦克公司3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7638638B2 (en)2003-05-142009-12-29Takeda San Diego, Inc.Dipeptidyl peptidase inhibitors
CA2525442A1 (en)2003-05-152004-11-25Taisho Pharmaceutical Co., Ltd.Cyanofluoropyrrolidine derivatives
EP1631679A2 (en)2003-05-212006-03-08Bayer HealthCare AGDiagnostics and therapeutics for diseases associated with dipeptidylpeptidase 7 (dpp7)
EP1631680A2 (en)2003-05-212006-03-08Bayer HealthCare AGDiagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
AU2003902828A0 (en)2003-06-052003-06-26Fujisawa Pharmaceutical Co., Ltd.Dpp-iv inhibitor
US20070099884A1 (en)2003-06-062007-05-03Erondu Ngozi ECombination therapy for the treatment of diabetes
DE602004026440D1 (en)2003-06-062010-05-20Merck Sharp & Dohme CONDENSED INDOLE AS A DIPEPTIDYL-PEPTIDASE INHIBITOR FOR THE TREATMENT OR PREVENTION OF DIABETES
AU2003902946A0 (en)2003-06-122003-06-26Fujisawa Pharmaceutical Co., Ltd.Dpp-iv inhibitor
JP4579239B2 (en)2003-06-172010-11-10メルク・シャープ・エンド・ドーム・コーポレイション Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7566707B2 (en)2003-06-182009-07-28Boehringer Ingelheim International GmbhImidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10327439A1 (en)2003-06-182005-01-05Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel imidazopyridazinone and imidazopyridone derivatives, their production and their use as pharmaceuticals
ATE437876T1 (en)2003-06-202009-08-15Hoffmann La Roche HEXAHYDROPYRIDOISOCHINOLINES AS DPP-IV INHIBITORS
ATE489387T1 (en)2003-06-202010-12-15Hoffmann La Roche PYRIDOÄ2,1-AÜ-ISOCHINOLINE DERIVATIVES AS DPP-IV INHIBITORS
JO2625B1 (en)2003-06-242011-11-01ميرك شارب اند دوم كوربوريشنPhosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
JP2005023038A (en)2003-07-042005-01-27Taisho Pharmaceut Co Ltd Chronic kidney disease treatment
MXPA06000725A (en)2003-07-212006-03-30Smithkline Beecham Corp(2s, 4s)-4-fluoro -1-[4-fluoro -beta-(4- fluorophenyl)- l-phenylalanyl] -2- pyrrolidinecarbonitrile p- toluenesulfonic acid salt and anhydrous crystalline forms thereof.
US7094800B2 (en)2003-07-252006-08-22Sanofi-Aventis Deutschland GmbhCyanopyrrolidides, process for their preparation and their use as medicaments
PE20050249A1 (en)2003-07-252005-06-01Aventis Pharma Gmbh NEW CYANOPYRROLIDES AND PROCEDURE FOR THEIR PREPARATION AS MEDICINES
US7008957B2 (en)2003-07-252006-03-07Sanofi-Aventis Deutschland GmbhBicyclic cyanoheterocycles, process for their preparation and their use as medicaments
DE10333935A1 (en)2003-07-252005-02-24Aventis Pharma Deutschland Gmbh New bicyclic cyano-heterocycles, process for their preparation and their use as pharmaceuticals
US20050065183A1 (en)2003-07-312005-03-24Indranil NandiFexofenadine composition and process for preparing
US7259160B2 (en)2003-07-312007-08-21Merck & Co., Inc.Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US6995183B2 (en)2003-08-012006-02-07Bristol Myers Squibb CompanyAdamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
DE10337074A1 (en)2003-08-122005-03-17Keyneurotek Ag Use of the inhibitors of enzymes with activities of aminopeptidase N and / or dipeptidyl peptidase IV and pharmaceutical preparations thereof for the therapy and prevention of chronic neurodegenerative diseases
US20050070531A1 (en)2003-08-132005-03-31Syrrx, Inc.Dipeptidyl peptidase inhibitors
US7169926B1 (en)2003-08-132007-01-30Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
WO2005019168A2 (en)2003-08-202005-03-03Pfizer Products Inc.Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
WO2005021550A1 (en)2003-08-292005-03-10Dainippon Sumitomo Pharma Co., Ltd.Bicyclic pyrazole derivative
HU227684B1 (en)2003-08-292011-11-28Sanofi AventisAdamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
AU2004268024B2 (en)2003-09-022007-07-12Merck Sharp & Dohme LlcNovel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US7205409B2 (en)2003-09-042007-04-17Abbott LaboratoriesPharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
WO2005023762A1 (en)2003-09-042005-03-17Abbott LaboratoriesPyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
US7790734B2 (en)2003-09-082010-09-07Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
JP2007513058A (en)2003-09-082007-05-24武田薬品工業株式会社 Dipeptidyl peptidase inhibitor
GB0321100D0 (en)2003-09-092003-10-08Celltech R&D LtdBiological products
AR046330A1 (en)2003-09-092005-12-07Japan Tobacco Inc DIPEPTIDILPEPTIDASA IV INHIBITOR
WO2005030127A2 (en)2003-09-232005-04-07Merck & Co., Inc.Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
CA2540741A1 (en)2003-10-032005-04-14Takeda Pharmaceutical Company LimitedAgent for treating diabetes
US7223761B2 (en)2003-10-032007-05-29Amgen Inc.Salts and polymorphs of a potent antidiabetic compound
WO2005033099A2 (en)2003-10-032005-04-14Glenmark Pharmaceuticals Ltd.Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
DE10348022A1 (en)2003-10-152005-05-25Imtm Gmbh New dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases
DE10348044A1 (en)2003-10-152005-05-19Imtm Gmbh Dual alanyl aminopeptidase and dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases
GB0324236D0 (en)2003-10-162003-11-19Astrazeneca AbChemical compounds
TW200519105A (en)2003-10-202005-06-16Lg Life Science LtdNovel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
US20070123470A1 (en)2003-10-242007-05-31Wladimir HogenhuisEnhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue
KR20100012105A (en)2003-10-312010-02-05다케다 야쿠힌 고교 가부시키가이샤Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
TW200523252A (en)2003-10-312005-07-16Takeda PharmaceuticalPyridine compounds
TW200528440A (en)2003-10-312005-09-01Fujisawa Pharmaceutical Co2-cyanopyrrolidinecarboxamide compound
EP1682120A4 (en)2003-11-042009-05-27Merck & Co IncFused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7317109B2 (en)2003-11-122008-01-08Phenomix CorporationPyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
AR046778A1 (en)2003-11-122005-12-21Phenomix Corp BORONIC ACID HETEROCICLIC COMPOUNDS. METHODS OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS.
US7767828B2 (en)2003-11-122010-08-03Phenomix CorporationMethyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20070149451A1 (en)2003-11-172007-06-28Holmes David GCombination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
CA2545641A1 (en)2003-11-172005-06-02Novartis AgUse of organic compounds
US20070105890A1 (en)2003-11-262007-05-10Dainippon Sumitomo Pharma Co., LtdNovel condensed imidazole derivative
DE10355304A1 (en)2003-11-272005-06-23Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 8- (piperazin-1-yl) and 8 - ([1,4] diazepan-1-yl) xanthines, their preparation and their use as pharmaceuticals
US7504423B2 (en)2003-12-112009-03-17Mitsubishi Tanabe Pharma Corporationα-amino acid derivatives and use thereof as medicines
WO2005058849A1 (en)2003-12-152005-06-30Glenmark Pharmaceuticals Ltd.New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them
US7217711B2 (en)2003-12-172007-05-15Boehringer Ingelheim International GmbhPiperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
DE10360835A1 (en)2003-12-232005-07-21Boehringer Ingelheim Pharma Gmbh & Co. KgNew bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis
EP1708571A4 (en)2004-01-162009-07-08Merck & Co IncNovel crystalline salts of a dipeptidyl peptidase-iv inhibitor
EP1559419A1 (en)2004-01-232005-08-03Fournier Laboratories Ireland LimitedPharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
KR20050076924A (en)2004-01-262005-07-29삼성전자주식회사I2c cummunication system capable of reciprocal communication and method thereof
WO2005075426A1 (en)2004-02-032005-08-18Glenmark Pharmaceuticals Ltd.Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
US7230002B2 (en)2004-02-032007-06-12Glenmark Pharmaceuticals Ltd.Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
US7501426B2 (en)2004-02-182009-03-10Boehringer Ingelheim International Gmbh8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
AU2005215136A1 (en)2004-02-202005-09-01Novartis AgDPP-IV inhibitors for treating neurodegeneration and cognitive disorders
BRPI0507971A (en)2004-02-232007-07-24Tufts College compound, pharmaceutical composition, use of a compound, method to inhibit the proteolytic activity of a postproline cleavage enzyme and packaged medicine
CA2558106A1 (en)2004-02-232005-09-09Trustees Of Tufts CollegeInhibitors of dipeptidylpeptidase iv for regulating glucose metabolism
DE102004009039A1 (en)2004-02-232005-09-08Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- [3-Amino-piperidin-1-yl] xanthines, their preparation and use as pharmaceuticals
US20050215603A1 (en)2004-03-082005-09-29Irini Akritopoulou-ZanzePharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7348346B2 (en)2004-03-082008-03-25Abbott LaboratoriesPharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
WO2005086904A2 (en)2004-03-082005-09-22Amgen Inc.Therapeutic modulation of ppar (gamma) activity
CA2559611C (en)2004-03-092012-01-17National Health Research InstitutesPyrrolidine compounds
US20070093492A1 (en)2004-03-092007-04-26Weir-Torn JiaangPyrrolidine derivatives
US7393847B2 (en)2004-03-132008-07-01Boehringer Ingleheim International GmbhImidazopyridazinediones, their preparation and their use as pharmaceutical compositions
WO2005095381A1 (en)2004-03-152005-10-13Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
WO2005092877A1 (en)2004-03-162005-10-06Boehringer Ingelheim International GmbhGlucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
US20050215882A1 (en)2004-03-232005-09-29The Regents Of The University Of MichiganNoninvasive method to determine fat content of tissues using MRI
TW200538122A (en)2004-03-312005-12-01Bristol Myers Squibb CoProcess for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein
US7179809B2 (en)2004-04-102007-02-20Boehringer Ingelheim International Gmbh2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7741082B2 (en)2004-04-142010-06-22Bristol-Myers Squibb CompanyProcess for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
JP4739189B2 (en)2004-04-142011-08-03武田薬品工業株式会社 Solid preparation
TW200536827A (en)2004-05-042005-11-16Bristol Myers Squibb CoEnzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors
JP2007538079A (en)2004-05-182007-12-27メルク エンド カムパニー インコーポレーテッド Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2005118555A1 (en)2004-06-042005-12-15Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
DE102004030502A1 (en)2004-06-242006-01-12Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel imidazoles and triazoles, their preparation and use as medicines
WO2006019965A2 (en)2004-07-162006-02-23Takeda San Diego, Inc.Dipeptidyl peptidase inhibitors
WO2006009149A1 (en)2004-07-212006-01-26Kissei Pharmaceutical Co., Ltd.Progression inhibitor for disease attributed to abnormal accumulation of liver fat
US7165453B2 (en)2004-07-232007-01-23Electric Power Research InstituteFlexible electromagnetic acoustic transducer sensor
US7054436B2 (en)2004-08-022006-05-30Sony Ericsson Mobile Communication, AbCommunication terminals with a dual use speaker for sensing background noise and generating sound, and related methods and computer program products
US20060046978A1 (en)2004-08-312006-03-02Morphochem AgNovel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)
DE102004043944A1 (en)2004-09-112006-03-30Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 8- (3-amino-piperidin-1-yl) -7- (but-2-ynyl) -xanthines, their preparation and their use as pharmaceuticals
DE102004044221A1 (en)2004-09-142006-03-16Boehringer Ingelheim Pharma Gmbh & Co. Kg New 3-methyl-7-butynyl xanthines, their preparation and their use as pharmaceuticals
WO2006034435A2 (en)2004-09-212006-03-30Point Therapeutics, Inc.Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
AR051446A1 (en)2004-09-232007-01-17Bristol Myers Squibb Co C-ARYL GLUCOSIDS AS SELECTIVE INHIBITORS OF GLUCOSE CONVEYORS (SGLT2)
NZ554515A (en)2004-10-122009-12-24Glenmark Pharmaceuticals SaNovel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation
MX2007004536A (en)2004-10-132007-07-17Univ ConnecticutCannabinergic lipid ligands.
US20060252670A1 (en)2004-10-142006-11-09Intercept Pharmaceuticals Inc.Method of reducing drug-induced adverse side effects in a patient
EP1656934A1 (en)2004-11-122006-05-17Cognis IP Management GmbHUse of physiologically active fatty acids for treating lipodystrophy
WO2006058628A2 (en)2004-11-302006-06-08F.Hoffmann-La Roche AgSubstituted benzoquinolizines as dpp-iv inhibitors for the treatment of diabetes
US7687469B2 (en)2004-12-162010-03-30Boehringer Ingelheim International GmbhGlucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
AU2005318597A1 (en)2004-12-202006-06-29F. Hoffmann-La Roche Ag4-aminopiperidine derivatives
US7411093B2 (en)2004-12-202008-08-12Hoffman-La Roche Inc.Aminocycloalkanes as DPP-IV inhibitors
EP1828192B1 (en)2004-12-212014-12-03Takeda Pharmaceutical Company LimitedDipeptidyl peptidase inhibitors
DOP2006000008A (en)2005-01-102006-08-31Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
EP1888571A2 (en)2005-03-222008-02-20F. Hoffmann-Roche AGNew salt and polymorphs of a dpp-iv inhibitor
WO2006116157A2 (en)2005-04-222006-11-02Alantos Pharmaceuticals Holding, Inc.Dipeptidyl peptidase-iv inhibitors
UA91546C2 (en)2005-05-032010-08-10Бьорінгер Інгельхайм Інтернаціональ ГмбхCrystalline form of 1-chloro-4-(я-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7723309B2 (en)2005-05-032010-05-25Boehringer Ingelheim International GmbhCrystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7644148B2 (en)2005-05-162010-01-05Hewlett-Packard Development Company, L.P.Historical data based workload allocation
US7521557B2 (en)2005-05-202009-04-21Bristol-Myers Squibb CompanyPyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US20060264433A1 (en)2005-05-232006-11-23Backes Bradley JPharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7825139B2 (en)2005-05-252010-11-02Forest Laboratories Holdings Limited (BM)Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060270722A1 (en)2005-05-312006-11-30Thornberry Nancy ACombination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity
EP1905450A1 (en)2005-07-122008-04-02Daiichi Sankyo Company, LimitedPharmaceutical composition containing ppar gamma agonist
BRPI0614732A2 (en)2005-08-112011-04-12Hoffmann La Roche A pharmaceutical composition comprising a dpp-iv inhibitor, use of a dpp-iv inhibitor and method for treating diseases associated with high blood glucose levels.
US7425633B2 (en)2005-08-262008-09-16National Health Research InstitutesPyrrolidine compounds
CA2620566A1 (en)2005-08-302007-03-08Boehringer Ingelheim International GmbhGlucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
US7834012B2 (en)2005-08-302010-11-16Abbott LaboratoriesPharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
AU2006289093A1 (en)2005-09-082007-03-15Boehringer Ingelheim International GmbhCrystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
AR056195A1 (en)2005-09-152007-09-26Boehringer Ingelheim Int PROCEDURES TO PREPARE DERIVATIVES OF (ETINIL-BENCIL) -BENZENE REPLACED GLUCOPYRANOSIL AND INTERMEDIATE COMPOUNDS OF THE SAME
AT502717A1 (en)2005-11-092007-05-15Omnica Gmbh PHARMACEUTICAL USE OF A COMPOUND
WO2007054577A1 (en)2005-11-142007-05-18Probiodrug AgCyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors
DE602006017259D1 (en)2005-12-212010-11-11Hoffmann La Roche NEW SALT AND POLYMORPH OF DPP-IV HEMMERS
TWI384985B (en)2005-12-222013-02-11Takeda PharmaceuticalSolid preparation
CA2635838A1 (en)2006-02-152007-08-23Boehringer Ingelheim International GmbhGlucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
US20070239536A1 (en)2006-04-052007-10-11General Electric CompanySystem and method for scheduling audience deficiency units and makegoods
PE20080697A1 (en)2006-05-032008-08-05Boehringer Ingelheim Int BENZONITRILE DERIVATIVES SUBSTITUTED WITH GLUCOPYRANOSIL, PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS OF THIS TYPE, THEIR USE AND PROCEDURE FOR THEIR MANUFACTURE
SI2032134T1 (en)2006-05-092015-10-30Genzyme CorporationMethods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
DE602007005139D1 (en)2006-07-212010-04-15Novartis Ag FORMULATIONS FOR BENZIMIDAZOLYLPYRIDYL ETHER
US8283326B2 (en)2006-10-272012-10-09Boehringer Ingelheim International GmbhCrystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
AR063569A1 (en)2006-11-062009-02-04Boehringer Ingelheim Int DERIVATIVES OF BENZIL- BENZONITRILE SUBSTITUTED WITH GLUCOPYRANOSIL MEDICINES CONTAINING COMPOUNDS OF THIS TYPE ITS USE OR PROCEDURE FOR MANUFACTURING
CA3007700A1 (en)2006-11-092008-05-15Boehringer Ingelheim International GmbhCombination therapy with sglt-2 inhibitors and their pharmaceutical compositions
US20080132555A1 (en)2006-11-282008-06-05Auspex Pharmaceuticals, Inc.Preparation and utility of substituted phenyltetrazoles
AU2007335191A1 (en)2006-12-212008-06-26Alphapharm Pty LtdPharmaceutical compound and composition
US20070172525A1 (en)2007-03-152007-07-26Ramesh SeshaAnti-diabetic combinations
CA2721133C (en)2007-04-132018-11-06Somaxon Pharmaceuticals, Inc.Low-dose doxepin formulations and methods of making and using the same
CA2693628A1 (en)2007-07-112009-01-15Cardoz AbNew combination for use in the treatment of imflammatory disorders
WO2009015179A1 (en)2007-07-232009-01-29Syndax Pharmaceuticals, Inc.Novel compounds and methods of using them
CN101361968B (en)2007-08-062011-08-03健能隆医药技术(上海)有限公司Use of interleukin-22 in treating fatty liver
WO2009097996A1 (en)2008-02-072009-08-13Sanofi-AventisUse of substituted phenylimidazolidines for producing medicaments for treating metabolic syndrome
WO2009097997A1 (en)2008-02-072009-08-13Sanofi-AventisSubstituted imidazolidine-2,4-diones, method for the production thereof, medicaments containing said compounds and use thereof
US20130245024A1 (en)2008-03-062013-09-19Dennis LanfearCombination of PPARy Agonist and a Dipeptidyl Peptidase-Inhibitor for the Treatment of Diabetes and Obesity
WO2009151116A1 (en)2008-06-132009-12-17持田製薬株式会社Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
US20100087481A1 (en)2008-10-032010-04-08Lee Kathleen MOral pharmaceutical formulations for antidiabetic compounds
JP2010265216A (en)2009-05-142010-11-25Takeda Chem Ind LtdHeterocyclic compound
PL2448412T3 (en)2009-07-012019-11-29Jds Therapeutics LlcChromium complexes as enhancers of brain glucose transporters
WO2011017488A2 (en)2009-08-052011-02-10Intekrin Therapeutics, Inc.Combination of a selective ppar-gamma modulator and an incretin for the treatment of diabetes and obesity
US8477001B2 (en)2010-09-212013-07-02Remy Technologies LlcStarter solenoid with rectangular coil winding
WO2012040082A2 (en)2010-09-212012-03-29Intekrin Therapeutics, Inc.Antidiabetic solid pharmaceutical compositions
CN103154257A (en)2010-09-262013-06-12大玉企业有限公司Method of recombinant macromolecular production
WO2012071459A1 (en)2010-11-222012-05-31The Regents Of The University Of CaliforniaNew indication for use of niacin (nicotinic acid) for treatment, prevention and reversal of fatty liver disease
TWI435605B (en)2010-11-292014-04-21Realtek Semiconductor CorpNetwork device and network connecting method for building up network connection via high definition multimedia interface
ES2389547B1 (en)2010-12-072013-08-08Consejo Superior De Investigaciones Científicas (Csic) BIFIDOBACTERIUM CECT 7765 AND ITS USE IN THE PREVENTION AND / OR TREATMENT OF OVERWEIGHT, OBESITY AND ASSOCIATED PATHOLOGIES.
US8865641B2 (en)2011-06-162014-10-21The Feinstein Institute For Medical ResearchMethods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
US9044433B2 (en)2011-10-062015-06-02Vanderbilt UniversityCompositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
WO2013071077A1 (en)*2011-11-092013-05-16Cornell UniversityThe use of pan-ppar agonists for prevention and treatment of huntington's disease and tauopathies
JP5525511B2 (en)2011-12-272014-06-18農業生産法人株式会社 熱帯資源植物研究所 Drugs for non-alcoholic fatty liver disease and / or non-alcoholic steatohepatitis
US9499472B2 (en)2012-03-052016-11-22The University Of MontanaAspartylamide inhibitors of excitatory amino acid transporters
JP6314142B2 (en)*2012-09-212018-04-18レオキシン ディスカバリーズ グループ,インコーポレイテッド Cell for electrolyzing liquid
PE20151435A1 (en)2012-10-122015-10-15Teva Pharma LAQUINIMOD TO REDUCE THALAMIC DAMAGE IN MULTIPLE SCLEROSIS
HK1218510A1 (en)2013-01-302017-02-24Intekrin Therapeutics, Inc.Ppart agonists for treatment of multiple sclerosis
EP2972386B1 (en)2013-03-152018-01-10Somalogic, Inc.Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
US10441560B2 (en)2013-03-152019-10-15Mochida Pharmaceutical Co., Ltd.Compositions and methods for treating non-alcoholic steatohepatitis
TWI696462B (en)2013-07-102020-06-21日商興和股份有限公司The therapeutic agent for nonalcoholic fatty liver disease
AU2014364447A1 (en)2013-12-202016-08-04Teva Pharmaceutical Industries Ltd.Use of laquinimod to delay Huntington's disease progression
CA2939833A1 (en)2014-02-272015-09-03Nusirt Sciences, Inc.Compositions and methods for the reduction or prevention of hepatic steatosis
CA2963354A1 (en)2014-10-102016-04-14Prometic Biosciences Inc.Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
CN104299589B (en)2014-10-292016-05-25京东方科技集团股份有限公司Shift register cell circuit, shift register, driving method and display unit
KR20160061492A (en)2014-11-212016-06-01삼성디스플레이 주식회사Portable dust senser and cellular phone using the same
EP3267994A4 (en)2015-03-092018-10-31Intekrin Therapeutics, Inc.Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
ES2974281T3 (en)2015-04-072024-06-26Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy
US10857209B2 (en)2016-02-122020-12-08Indiana University Research And Technology CorporationLysosomal acid lipase and PPAR gamma ligands as immune therapies for cancer treatment
SG11201809882XA (en)2016-06-082018-12-28Support Venture GmbhPharmaceutical combinations for treating cancer
US20190167660A1 (en)2016-08-182019-06-06Intekrin Therapeutics, Inc.PPAR-gamma AGONIST FOR TREATMENT OF BONE DISORDERS
MX2019001979A (en)2016-08-182019-09-19Intekrin Therapeutics IncPPARy AGONIST FOR TREATMENT OF BLOOD CANCERS.
CN110461318A (en)2016-09-132019-11-15因特克林治疗股份有限公司 Treatment of Multiple Sclerosis with CHS-131
US11350844B2 (en)2016-11-232022-06-07Mayo Foundation For Medical Education And ResearchSystem and method for generating nonalcoholic fatty liver disease activity score (NAS) using magnetic resonance elastography
AU2018206907B2 (en)2017-01-112023-11-02Kowa Company, Ltd.Prophylactic and therapeutic drug for nonalcoholic fatty liver disease
EA201991716A1 (en)2017-01-182020-02-04Кохерус Байосайенсис, Инк. PPARγ AGONIST FOR TREATMENT OF GENTINGTON DISEASE
MX2019011867A (en)2017-04-032020-01-09Coherus Biosciences IncPparî³ agonist for treatment of progressive supranuclear palsy.
BR112019021910A2 (en)2017-04-182020-05-26Genfit COMBINATION OF ELAFIBRANOR OR DERIVATIVES OF THE SAME WITH AN ANTI-NASH, ANTIFIBROTIC OR ANTICOLESTATIC AGENT
EA201992364A1 (en)2018-04-022020-03-23Кохерус Байосайенсис Инк. PPARγ AGONIST FOR TREATMENT OF PROGRESSING NUCLEAR PARALYSIS
EP3906022A1 (en)2018-12-312021-11-10Coherus Biosciences, Inc.Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)

Also Published As

Publication numberPublication date
IL269705A (en)2019-11-28
EP3606527A1 (en)2020-02-12
CN110996951A (en)2020-04-10
MX2019011867A (en)2020-01-09
JP2020515639A (en)2020-05-28
CA3058806A1 (en)2018-10-11
KR20200036808A (en)2020-04-07
WO2018187350A1 (en)2018-10-11
US20210283121A1 (en)2021-09-16
BR112019020485A2 (en)2020-05-12
AU2018249822A1 (en)2019-10-31
US11253508B2 (en)2022-02-22

Similar Documents

PublicationPublication DateTitle
SG11201903938XA (en)Acylated glp-1/glp-2 dual agonists
SG11201909960UA (en)Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201909963YA (en)Methods for treating dravet syndrome
SG11201807279QA (en)Binding proteins and methods of use thereof
SG11201900480YA (en)Anti-tim-3 antibodies
SG11201809344QA (en)Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201909022PA (en)ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201810420YA (en)Antibodies to alpha-synuclein and uses thereof
SG11201910134SA (en)Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201908238SA (en)Anti-c5 antibodies and uses thereof
SG11201901558VA (en)Pth compounds with low peak-to-trough ratios
SG11201807597UA (en)Methods of treating depression using orexin-2 receptor antagonists
SG11201808222RA (en)Methods of treatment of cholestatic diseases
SG11201909046XA (en)PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
SG11201909224QA (en)Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
SG11201901576QA (en)Dosage regimen for a controlled-release pth compound
SG11201808710UA (en)Novel immunogenic cd1d binding peptides
SG11201809764XA (en)Humanized anti-il-1r3 antibodies
SG11201907693VA (en)Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
SG11201900486WA (en)Treatment and prevention of sleep disorders
SG11201808676RA (en)Methods of treating pediatric cancers
SG11201906436VA (en)Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201901070YA (en)Formulations for oral administration of active agents
SG11201807255YA (en)Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
SG11201906963QA (en)Binding agents

[8]ページ先頭

©2009-2025 Movatter.jp